Resources from the same session
FIRE-4 (AIO-KRK-0114): Randomized study for a switch maintenance concept with 5-FU plus bevacizumab after induction treatment with FOLFIRI plus cetuximab versus continued treatment with FOLFIRI plus cetuximab-secondary endpoint
Presenter: Volker Heinemann, Germany
Session: Session X: Presentation of Selected Colorectal Cancer Abstracts
Resources:
Slides
A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer
Presenter: Feng Wang, China
Session: Session X: Presentation of Selected Colorectal Cancer Abstracts
Resources:
Slides
Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: pooled analysis of PRECONNECT and TALLISUR studies
Presenter: Lucjan Wyrwicz, Poland
Session: Session X: Presentation of Selected Colorectal Cancer Abstracts
Resources:
Slides
Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer
Presenter: Hiroya Taniguchi, Japan
Session: Session X: Presentation of Selected Colorectal Cancer Abstracts
Resources:
Slides
SO-20: Stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: An exploratory analysis of the CORRECT trial
Presenter: Christophe Borg, France
Session: Session X: Presentation of Selected Colorectal Cancer Abstracts
Resources:
Slides
Discussant: SO-18, SO-19, SO-20, SO-21
Presenter: Tanios Bekaii-Saab, United States
Session: Session X: Presentation of Selected Colorectal Cancer Abstracts
Resources:
Slides
Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: an individual patient data pooled analysis of clinical trials
Presenter: Alessandra Raimondi, Italy
Session: Session X: Presentation of Selected Colorectal Cancer Abstracts
Resources:
Slides
Clinical classification-based evaluation of adjuvant therapy with oxaliplatin in stage II colon cancer
Presenter: Benoist Chibaudel, France
Session: Session X: Presentation of Selected Colorectal Cancer Abstracts
Resources:
Slides
Real-world evaluation of clinical utility of ColonAiQ® , a blood-based assay for colorectal cancer (CRC) early Detection
Presenter: Yanbing Ding, China
Session: Session X: Presentation of Selected Colorectal Cancer Abstracts